

### REMARKS/ARGUMENTS

The Claims in the case are 1-5, 12, and 16. Claims 9-11 and 13-14 were cancelled in the preliminary amendment filed June 15, 2006. Claims 6-8, 15 and 17-18 were cancelled in the previous paper filed May 21, 2008. A response to an earlier restriction requirement was filed December 22, 2008.

The Examiner has made a third restriction requirement listing 10 groups. Applicants elect Group IX for examination, drawn to compounds wherein

$a^1-a^2=a^3-a^4$  is N-CH=CH-CH and


Z is NH;

$X^1$  is  $NR^{11}$ ;

$X^2$  is O or  $O-C_{1-2}$  alkyl;

and Y is  $C_{3-9}$  alkyl or  $C_{3-9}$  alkenyl.

For search purposes, Applicants elect as species, the compound 1 having the name of 7*H*,19*H*-4,6-ethanediylidenepyrimido[4,5-*b*][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-.



The structure of this compound is , which is the compound prepared in Example B1 at page 41 of the Specification. The elected compound falls within Group IX. The claims remaining in the application: 1-5, 12, and 16, read on the elected group.

Examination on the merits is respectfully requested.

Respectfully submitted,

/Hesna J. Pfeiffer/

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
Phone: (732) 524-2830  
Dated: June 12, 2009

By: \_\_\_\_\_  
Hesna J. Pfeiffer, Reg. 22,640